[CKD-MBD and cardiovascular disease.]

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Cardiovascular disease (CVD) is a leading cause of mortality in patients with chronic kidney disease (CKD).
• Mineral bone disorder (MBD) is increasingly recognized as a significant contributor to CVD progression in CKD.
• Phosphate dysregulation plays a central role in the pathophysiology of MBD and CVD in CKD.

Purpose of the Study:

• To elucidate the intricate mechanisms linking mineral bone disorder to cardiovascular disease progression in chronic kidney disease.
• To highlight the critical role of phosphate homeostasis in the development and advancement of CVD in CKD patients.

Main Methods:

• Review of current literature on mineral bone disorder and cardiovascular disease in chronic kidney disease.
• Analysis of the biochemical pathways involving phosphate, parathyroid hormone, fibroblast growth factor 23, and active vitamin D.
• Examination of direct and indirect effects of phosphate on cardiovascular health.

Main Results:

• Elevated phosphate levels directly and indirectly impact the cardiovascular system.
• Phosphate influences key hormonal regulators including parathyroid hormone, fibroblast growth factor 23, and active vitamin D.
• These hormonal changes mediate and exacerbate cardiovascular complications in CKD.

Conclusions:

• Understanding the mechanisms of CVD progression driven by MBD is crucial for CKD patient outcomes.
• Targeting mineral bone disorder, especially phosphate control, is essential for managing and preventing CVD in chronic kidney disease.